Figure 2
From: TH17 cells express ST2 and are controlled by the alarmin IL-33 in the small intestine
TH17 cells express ST2 in vivo upon anti-CD3 treatment. IL17A-eGFPxFoxp3-mRFP reporter mice were injected i.p. with anti-CD3 at day 1, 3 and 5. Flow cytometry analysis of TH17 cells (gated as Foxp3−IL-17A+) and Tregs (gated as IL-17A−Foxp3+) contained in the ST2+ T-cell population at steady state and during anti-CD3 treatment from the SI (a) and the spleen (b). (c) Frequencies of ST2+ TH17 and ST2+ Tregs at steady state and during anti-CD3 treatment in both tissues, gated as in a–b. (d) Flow cytometry analysis of ST2 and CCR6 in splenic TH17 and Tregs after anti-CD3 treatment (day 5). (e) Comparison of the mean fluorescence intensity of ST2 in TH17 cells during anti-CD3 treatment in spleen and SI. Data are shown as mean±s.e.m. and are representative of two independent experiments (n=5 animals per group). *P<0,05, ****P<0,0001 as calculated by two-way Anova with Bonferroni post-test. ns, not significant. Backgating strategy and controls for ST2 staining shown in Supplementary Figure S2a and b, respectively.
